Blood Cancer

AstraZeneca Says Calquence/Chemo Combo Data Shows Additional 16.8 Months Without Disease Progression In Patients With Certain Type Of Blood Cancer

House Majority Leader Steve Scalise Diagnosed With Treatable Blood Cancer

Gilead Withdraws Use Of Zydelig In Two Forms Of Blood Cancer In US

House Majority Leader Steve Scalise Diagnosed With Treatable Blood Cancer

Gilead Withdraws Use Of Zydelig In Two Forms Of Blood Cancer In US

Takeda's Breakthrough Blood Cancer Drug Flunks In Phase 3 Study

Pfizer Beefs Up Blood Cancer Pipeline With Trillium Acquisition: See Highlights

Takeda's Breakthrough Blood Cancer Drug Flunks In Phase 3 Study

Pfizer Beefs Up Blood Cancer Pipeline With Trillium Acquisition: See Highlights

BeiGene's Brukinsa Prolongs Progression-Free Survival Compared To Chemo In Untreated Blood Cancer Patients

Magenta Therapeutics Stock Drops As FDA Issues Clinical Hold On Blood Cancer Candidate IND

Blood Cancer Recent News

Caribou Biosciences Eyes $100M NASDAQ Debut To Propel Off-The-Shelf CAR-T Therapies In Blood Cancer

Precision BioSciences Starts Dosing In Blood Cancer Trial With CAR T Therapy

Jazz Pharma's Rylaze Scores FDA Approval For Blood Cancer

Salarius Pharmaceuticals Launches Mid-Stage Blood Cancer Trial With Seclidemstat

Protagonist Stock Moves Higher As Rusfertide Shows Durability Of Effect, Symptom Improvements In Blood Cancer Trial

Curis Shares Drop After Updated CA-4948 Data From Mid-Stage Blood Cancer Trial

Allogene's Stock Jumps After Blood Cancer Candidates Show Durable Response

BeiGene's Brukinsa On Par With JNJ's Imbruvica In Late-Stage Blood Cancer Studies

Humanigen's Lenzilumab Shows Encouraging Response Rate In Blood Cancer Study

Karyopharm's Selinexor Receives Conditional Approval In Europe For Type Of Blood Cancer

The European Commission has granted conditional marketing authorization for Karyopharm

Bluebird bio Says Lentiviral Vector Not the Cause Of Blood Cancer Reported In Sickle Cell Study

Based on multiple independent analyses, Bluebird bio Inc (NASDAQ: BLUE) has

Innate Pharma To Test Lacutamab In Relapsed/Refractory Peripheral T-Cell Lymphoma Patients